Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Intramural Research (Z01)
Project #
1Z01ES048006-94
Application #
3755435
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
94
Fiscal Year
1994
Total Cost
Indirect Cost
City
State
Country
United States
Zip Code
Lee, Su-Jun; Bell, Douglas A; Coulter, Sherry J et al. (2005) Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotype. J Pharmacol Exp Ther 313:302-9
Blaisdell, Joyce; Jorge-Nebert, Lucia F; Coulter, Sherry et al. (2004) Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics 14:527-37
Lee, Su-Jun; Usmani, Khawja A; Chanas, Brian et al. (2003) Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. Pharmacogenetics 13:461-72
Blaisdell, Joyce; Mohrenweiser, Harvey; Jackson, Jonathan et al. (2002) Identification and functional characterization of new potentially defective alleles of human CYP2C19. Pharmacogenetics 12:703-11
Tsao, C C; Wester, M R; Ghanayem, B et al. (2001) Identification of human CYP2C19 residues that confer S-mephenytoin 4'-hydroxylation activity to CYP2C9. Biochemistry 40:1937-44
Ibeanu, G C; Blaisdell, J; Ferguson, R J et al. (1999) A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. J Pharmacol Exp Ther 290:635-40